Viewing nowCombinationMDBICA Tablet 5/20 mg (Amlodipine Besilate, Olmesartan Medoxomil)
Olmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
IYUN Pharmaceutical Co., Ltd.

MFDS item code 201603461 · Approved 2016.06.14 · Insurance code 658603360
Treatment of essential hypertension not controlled with monotherapy
This medication is used for appropriately managing blood pressure in patients with essential hypertension for whom adequate control is challenging with monotherapy of amlodipine or olmesartan medoxomil. It effectively lowers blood pressure, helping to reduce the risk of cardiovascular complications and improve health.
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not adequately controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. Recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Precautions for Use, section 2. Patients in whom the medicine must not be administered.) ○ Elderly patients: Treatment is generally initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbid conditions should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients.
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients allergic to any component of this medication, pregnant or breastfeeding women, patients with severe liver impairment, or severe aortic stenosis should not take this medication. Patients with depletion of fluids or salts may experience hypotension when starting this medication, so they should carefully monitor their condition after starting treatment. If hypotension occurs, appropriate measures should be taken. Acute hypotension can rarely occur due to the vasodilatory effects, so close attention is needed in patients with severe aortic stenosis. Patients with severe coronary artery obstruction may have an increased risk of angina or myocardial infarction when taking this medication, thus caution is advised. Patients with heart failure should be monitored carefully, and patients with impaired renal function may experience changes in kidney function, necessitating regular tests. Patients with weakened liver function should take this medication with caution, and as it is metabolized in the liver, liver impairment patients should consult with their doctor before taking. Common side effects such as dizziness, headache, hypotension, dyspepsia, and edema may occur during treatment; persistent abnormal symptoms should be discussed with a healthcare professional. Administration during pregnancy poses significant risks to the fetus, so any pregnancy plans or existing pregnancies must be reported to a healthcare professional. Breastfeeding women are advised to stop nursing or discontinue the medication, as it may be passed into breast milk. Safety and efficacy in pediatric patients have not been established, so it is advisable not to administer to individuals under 18 years of age. Elderly patients should start at a lower dose considering potential renal and liver function decline, and should closely monitor for adverse reactions during treatment. In cases of overdose, symptoms related to hypotension and vasodilation may occur, requiring immediate medical treatment. This medication should be stored in a tightly sealed container, away from direct sunlight and moisture, and kept out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is safe to store it at a temperature between 1 to 30 degrees Celsius. Therefore, avoid direct sunlight, high or low temperatures, and keep it out of the reach of children.
White, round film-coated tablets
28 tablets (14 tablets/PTP packaging x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
IYUN Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.